BRWA
AVDL

B. Riley Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

B. Riley Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,000
Closed -$137K – 1543
2023
Q1 		$137K Hold
15,000
– – ﹤0.01% 1345
2022
Q4 		$107K Hold
15,000
– – ﹤0.01% 1352
2022
Q3 		$76K Hold
15,000
– – ﹤0.01% 1354
2022
Q2 		$37K Hold
15,000
– – ﹤0.01% 1182
2022
Q1 		$103K Buy
+15,000
New +$103K ﹤0.01% 1295
2015
Q1 		– Sell
-1,000
Closed -$17 – 671
2014
Q4 		$17 Buy
+1,000
New +$14.3K ﹤0.01% 2617

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

B. Riley Wealth Advisors's AVDL Position: Q2 2023 in Review

B. Riley Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 15,000 shares — an estimated $137K sold.

B. Riley Wealth Advisors first reported a position in AVDL in Q4 2014 and held it in 6 quarters. The position peaked at $137K in Q1 2023. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • B. Riley Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 15,000 Avadel Pharmaceuticals shares in Q2 2023, an estimated $137K.
  • B. Riley Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • B. Riley Wealth Advisors's Avadel Pharmaceuticals position peaked at $137K in Q1 2023.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2023, filed 27 Jul 2023.